Tapahtumakalenteri
iCAN science seminar: Dr. Daniel Hodson
Host: Prof. Sirpa Leppä
Minibio:
Dr Hodson studied medicine at Cambridge and Oxford Universities before training
in clinical haematology in Cambridge. He undertook a University of Cambridge
PhD in molecular immunology supervised by Dr Martin Turner at the Babraham
Institute. In 2010 he moved as a Kay Kendall Leukaemia Fund (KKLF)
Post-doctoral Fellow to the lab of Dr Louis Staudt at the National Cancer
Institute, NIH, USA to study the functional genomics of aggressive B cell
lymphoma. In 2015 he was awarded a Medical Research Council (MRC)
Clinician Scientist Fellowship and returned to Cambridge to establish a
research group in the Welcome MRC Cambridge Stem Cell Institute, University of
Cambridge. In 2021 he was awarded a Cancer Research UK Senior Research
Fellowship and in 2023 a European Research Council Consolidator award.
Seminar by Associate Professor Yoshifumi Itoh
Short biography:
After receiving his Msc in Pharmaceutical Sciences from Tokyo College of Pharmacy in Japan, in 1991 Dr Itoh moved to the University of Kansas Medical Center, USA to work with Prof Hideaki Nagase.
Using his research outcomes, he received a PhD from the Tokyo University of Pharmacy and Life Sciences, Japan, in 1996. In 1997 he became an Assistant Professor in Prof Motoharu Seiki's department at the Institute of Medical Sciences, University of Tokyo.
In 2001 he then moved to the Kennedy Institute of Rheumatology, Imperial College London to run his own lab and relocated to Oxford when the Kennedy Institute joined the University of Oxford.
His major scientific interests have been centered on mechanisms of cellular invasion and tissue destruction, especially in the aspects of arthritis and cancer, as they share common mechanisms and pathways.
Selected publications
1. Itoh Y (2022) Proteolytic modulation of tumor microenvironment signals during cancer progression. Front Oncol, 12, 935231
2. Gifford V, Woskowicz A, Ito N, Balint S, Lagerholm BC, Dustin ML, Itoh Y (2022) Coordination of two kinesin superfamily motor proteins, KIF3A and KIF13A, is essential for pericellular matrix degradation by membrane-type 1 matrix metalloproteinase (MT1-MMP) in cancer cells. Matrix Biology, 107, 1-23.
3. Itoh Y, Ng M, Wiberg A, Inoue K, Hirata N, Paiva KBS, Ito N, Dzobo K, Sato N, Gifford V, Fujita Y, Inada M, and Furniss D, (2021) A common SNP risk variant MT1-MMP causative for Dupuytren's Disease has a specific defect in collagenolytic activity. Matrix Biol, 97, 20-39.
4. Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A and Itoh Y (2016) Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of inflammatory arthritis: synergy with TNF blockade. Arthritis Rheum 68 (2), 521-531
5. Woskowicz AM, Weaver SA, Shitomi Y, Ito N, Itoh Y. (2013) MT-LOOP-dependent localization of MT1-MMP to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem. 288, 35126-37.
Kliinisen mikrobiologian perjantaisarja
Helsingin yliopiston eläinlääketieteellinen tiedekunta
Dissertation: Eliisa Nissilä
Opponent: professor Janne Liisanantti, University of Oulu
Dissertation: Leo Meriranta
Opponent: doctor Daniel Hodson, University of Cambridge